Prevalence and factors associated with fixed-dose combination antiretroviral drugs adherence among HIV-positive pregnant women on option B treatment in Mpumalanga province, South Africa

SOURCE: International Journal of Environmental Research and Public Health
OUTPUT TYPE: Journal Article
PUBLICATION YEAR: 2018
TITLE AUTHOR(S): S.Ramlagan, K.Peltzer, A.C.Ruiter, N.A.Barylski, S.M.Weiss, S.W.Sifunda
KEYWORDS: ANTIRETROVIRAL THERAPY (ART), HIV/AIDS TREATMENT, MPUMALANGA PROVINCE, PREGNANCY, WOMEN
DEPARTMENT: Public Health, Societies and Belonging (HSC)
Print: HSRC Library: shelf number 10167
HANDLE: 20.500.11910/11662
URI: http://hdl.handle.net/20.500.11910/11662

Download this report

If you would like to obtain a copy of this Research Output, please contact Hanlie Baudin at researchoutputs@hsrc.ac.za.

Abstract

The possibility for all babies to be born and remain HIV-negative for the first year of life is achievable in South Africa. HIV-positive mothers??? adherence to their antiretroviral medication is one of the crucial factors to achieve this target. Cross-sectional data were collected at 12 community health centres, over 12 months (2014???2015), from 673 HIV-positive women, less than 6 months pregnant, attending antenatal care, and on Option B treatment. Adherence measures included the Adults AIDS Clinical Trials Group (AACTG) four-day measure, as well as the Visual Analog Scale (VAS) seven-day measure. Bivariate analyses and multivariate logistic regressions are presented. 78.8% of respondents were adherent on AACTG, while 68.8% reported VAS adherence. Bivariate analyses for increased adherence show significant associations with older age, less/no alcohol usage, disclosure of HIV status, higher HIV knowledge, no desire to avoid ARV side effects, low stigma, and low depression. AACTG showed a negative association with intimate partner violence. Multivariable logistic regression on AACTG and VAS adherence rates resulted in unique contributions to increased adherence of older age, less/no alcohol usage, higher HIV knowledge, lack of depression, and non-disclosure. Programs targeting closer side effect monitoring, HIV disclosure, pre-natal depression, alcohol intake, and HIV knowledge need consideration.